| Name | 4SC-203 |
| Description | 4SC-203 is a multi-kinase inhibitor with potential anti-tumor activity. 4SC-203 exhibits unique selectivity for Flt3, Flt3 mutants, Axl, Alk, Fak, VEGF-R2, and Trk receptors in the low nM range. |
| In vitro | 4SC-203 exhibits unique selectivity in the low nM range for Flt3, Flt3 mutants, Axl, Alk, Fak, VEGF-R2, and Trk receptors.[1] |
| In vivo | In preclinical studies, 4SC-203 demonstrated significant antitumor activity in in vivo models relevant to acute myeloid leukemia. In a first-in-human study in healthy volunteers, 4SC-203 was shown to be well tolerated across the concentration range studied and to have a favorable pharmacokinetic profile.[1] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : Slightly soluble
|
| Keywords | VEGFR | Vascular endothelial growth factor receptor | tumor | multikinase | Inhibitor | inhibit | Fms like tyrosine kinase 3 | FLT3/STK1 | FLT3 | Cluster of differentiation antigen 135 | CD135 | antineoplastic | 4SC-203 | 4SC203 | 4SC 203 |
| Inhibitors Related | Ribociclib | Gilteritinib | Sorafenib | Pexidartinib | glycine | Nintedanib esylate | Regorafenib | Chloramphenicol | Thymoquinone | Lenvatinib | Pazopanib | Albendazole |
| Related Compound Libraries | Bioactive Compound Library | Membrane Protein-targeted Compound Library | ReFRAME Related Library | Tyrosine Kinase Inhibitor Library | Kinase Inhibitor Library | Hematonosis Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Bioactive Compounds Library Max | Anti-Cancer Active Compound Library | Anti-Cancer Drug Library |